STOK STOKE THERAPEUTICS INC Product Launches 8-K Filing 2023 - Product Updates Stoke Therapeutics, Inc. released new safety and efficacy data from its ongoing Phase 1/2a MONARCH, ADMIRAL and SWALLOWTAIL studies for its product STK-001 for treating Dravet syndrome.Get access to all SEC 8-K filings of the STOKE THERAPEUTICS INC